NasdaqGS:VTRSPharmaceuticals
Assessing Viatris (VTRS) Valuation After Earnings Beat Guidance Reaffirmation And Pipeline Progress
Viatris (VTRS) has been back in focus after quarterly revenue and earnings topped analyst estimates, management reaffirmed full year guidance, and investors heard fresh updates on cost savings and the drug pipeline.
See our latest analysis for Viatris.
The share price reaction has been strong, with a 9.03% 1 day share price return and a 32.14% 30 day share price return. In addition, the 1 year total shareholder return of 100.23% signals powerful momentum that has built over time.
If Viatris...